Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes?

Fifty-seven highly recurrent unipolar patients, excluded from previous long-term studies with selective serotonin reuptake inhibitors (SSRIs) after they experienced a new recurrence, were acutely treated with the full dosage of the SSRIs they were on. Fifty-one of them (89.5%) had a sustained respon...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2000-09, Vol.96 (1), p.81-85
Main Authors: Franchini, Linda, Rossini, David, Bongiorno, Fanny, Spagnolo, Chiara, Smeraldi, Enrico, Zanardi, Raffaella
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Depressive Disorder - drug therapy
Depressive Disorder - prevention & control
Dose-Response Relationship, Drug
Female
Fluvoxamine - administration & dosage
Humans
Long-term treatment
Male
Medical sciences
Middle Aged
Neuropharmacology
Paroxetine - administration & dosage
Pharmacology. Drug treatments
Proportional Hazards Models
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Recurrence
Risk Factors
Secondary Prevention
Selective serotonin reuptake inhibitors
Serotonin Uptake Inhibitors - administration & dosage
Sertraline - administration & dosage
Severity of Illness Index
Treatment Outcome
Unipolar depression
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fifty-seven highly recurrent unipolar patients, excluded from previous long-term studies with selective serotonin reuptake inhibitors (SSRIs) after they experienced a new recurrence, were acutely treated with the full dosage of the SSRIs they were on. Fifty-one of them (89.5%) had a sustained response and entered into the 4-month continuation therapy. During this phase, no relapse was observed. At the end of it, all patients gave their written informed consent to be enrolled in a 24-month long-term therapy, maintaining the same treatment dosage of fluvoxamine 300 mg/day, sertraline 150 mg/day, or paroxetine 40 mg/day. At the end of the study, 28 out of the 51 outpatients (54.9%) showed a further recurrence. Nevertheless, second recurrences observed during this second maintenance therapy were less severe than first recurrences, decreasing from 25.1±3.4 to 21.6±3.3 ( P
ISSN:0165-1781
1872-7123
DOI:10.1016/S0165-1781(00)00188-8